Evidence map›Paper›PMID 29873739›Full record

Trial reportThe Journal of infectious diseases2018

Impact of Antimicrobial Treatment for Acute Otitis Media on Carriage Dynamics of Penicillin-Susceptible and Penicillin-Nonsusceptible Streptococcus pneumoniae.

Joseph A Lewnard, Paula A Tähtinen, Miia K Laine, Laura Lindholm, Jari Jalava, Pentti Huovinen, Marc Lipsitch, Aino Ruohola

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in The Journal of infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Frequency of bystander exposure to antibiotics for enteropathogenic bacteria among young children in low-resource settings.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  6. Article
  7. Panel 3: Genomics, precision medicine and targeted therapies.International journal of pediatric otorhinolaryngology · 2020
    Review
  8. Article
  9. Review
  10. Article
  11. Balancing Benefits and Risks of Antibiotic Use.The Journal of infectious diseases · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Joseph A LewnardCenter for Communicable Disease Dynamics, Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Paula A TähtinenDepartment of Pediatrics and Adolescent Medicine, Turku University Hospital, Turku.
Miia K LaineDepartment of Pediatrics and Adolescent Medicine, Turku University Hospital, Turku.
Laura LindholmExpert Microbiology Unit, National Institute for Health and Welfare, Helsinki, Finland.
Jari JalavaInfectious Disease Control and Vaccinations Unit, National Institute for Health and Welfare, Helsinki, Finland.
Pentti HuovinenDepartment of Medical Microbiology and Immunology, University of Turku, Turku.
Marc LipsitchCenter for Communicable Disease Dynamics, Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Aino RuoholaDepartment of Pediatrics and Adolescent Medicine, Turku University Hospital, Turku.

Funding

Understanding and controlling antibiotic resistanceU54GM088558 · NIGMS · HARVARD SCHOOL OF PUBLIC HEALTH · PI LIPSITCH, MARC · 2009 to 2018
$26.4M
NIGMS NIH HHS U54 GM088558
6 · The paper itself

Abstract

Background: Despite concerns that antimicrobial treatment of prevalent infections may select for drug-resistant bacteria, the effects of antimicrobial treatment on colonization dynamics have not been well quantified. Methods: We measured impacts of antimicrobial treatment on nasopharyngeal carriage of penicillin-susceptible Streptococcus pneumoniae (PSSP) and penicillin-nonsusceptible (PNSP) lineages at the end of treatment and 15, 30, and 60 days after treatment in a previously conducted randomized, double-blinded, placebo-controlled trial of amoxicillin-clavulanate for stringently defined acute otitis media. Results: In intention-to-treat analyses, immediate treatment with amoxicillin-clavulanate reduced PSSP carriage prevalence by 88% (95% confidence interval [CI], 76%-96%) at the end of treatment and by 27% (-3%-49%) after 60 days but did not alter PNSP carriage prevalence. By the end of treatment, 7% of children who carried PSSP at enrollment remained colonized in the amoxicillin-clavulanate arm, compared with 61% of PSSP carriers who received placebo; impacts of amoxicillin-clavulanate persisted at least 60 days after treatment among children who carried PSSP at enrollment. Amoxicillin-clavulanate therapy reduced PSSP acquisition by >80% over 15 days. Among children who carried PNSP at enrollment, no impacts on carriage prevalence of S. pneumoniae, PSSP, or PNSP were evident at follow-up visits. Conclusions: Although the absolute risk of carrying PNSP was unaffected by treatment, antimicrobial therapy conferred a selective impact on colonizing pneumococci by accelerating clearance and delaying acquisition of PSSP.

Indexed as

Acute DiseaseAmoxicillinAnti-Bacterial AgentsClavulanic AcidDouble-Blind MethodFemaleHumansInfantMaleMicrobial Sensitivity TestsNasopharynxOtitis MediaPenicillinsPneumococcal InfectionsStreptococcus pneumoniaeAmoxicillinAnti-Bacterial AgentsClavulanic AcidPenicillins

Identifiers

PMID29873739
PMCPMC6151080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.